In vivo manipulation of V9V2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients

S. Meraviglia, M. Eberl, D. Vermijlen, M. Todaro, S. Buccheri, G. Cicero, C. La Mendola, G. Guggino, M. D'Asaro, V. Orlando, F. Scarpa, A. Roberts, N. Caccamo, G. Stassi, F. Dieli, A. C. Hayday

Research output: Contribution to journalArticle

Abstract

The potent anti-tumour activities of γδ T cells have prompted the development of protocols in which γδ-agonists are administered to cancer patients. Encouraging results from small Phase I trials have fuelled efforts to characterize more clearly the application of this approach to unmet clinical needs such as metastatic carcinoma. To examine this approach in breast cancer, a Phase I trial was conducted in which zoledronate, a Vγ9Vδ2 T cell agonist, plus low-dose interleukin (IL)-2 were administered to 10 therapeutically terminal, advanced metastatic breast cancer patients. Treatment was well tolerated and promoted the effector maturation of Vγ9Vδ2 T cells in all patients. However, a statistically significant correlation of clinical outcome with peripheral Vγ9Vδ2 T cell numbers emerged, as seven patients who failed to sustain Vγ9Vδ2 T cells showed progressive clinical deterioration, while three patients who sustained robust peripheral Vγ9Vδ2 cell populations showed declining CA15-3 levels and displayed one instance of partial remission and two of stable disease, respectively. In the context of an earlier trial in prostate cancer, these data emphasize the strong linkage of Vγ9Vδ2 T cell status to reduced carcinoma progression, and suggest that zoledronate plus low-dose IL-2 offers a novel, safe and feasible approach to enhance this in a subset of treatment-refractory patients with advanced breast cancer.

Original languageEnglish
Pages (from-to)290-297
Number of pages8
JournalClinical and Experimental Immunology
Volume161
Issue number2
DOIs
Publication statusPublished - Aug 2010

Keywords

  • cytokines
  • cytotoxicity
  • immunotherapy
  • metastatic breast cancer
  • Vγ9Vδ2 T cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'In vivo manipulation of V9V2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Meraviglia, S., Eberl, M., Vermijlen, D., Todaro, M., Buccheri, S., Cicero, G., La Mendola, C., Guggino, G., D'Asaro, M., Orlando, V., Scarpa, F., Roberts, A., Caccamo, N., Stassi, G., Dieli, F., & Hayday, A. C. (2010). In vivo manipulation of V9V2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clinical and Experimental Immunology, 161(2), 290-297. https://doi.org/10.1111/j.1365-2249.2010.04167.x